Citi analyst Joel Beatty raised his price target for Vanda Pharmaceuticals to $47 and keeps a Buy rating on the shares citing the “strong” Phase 2 tradipitant gastroparesis results. The analyst also raised his probability of approval to 65% from 40%.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.